Brokerages Expect Johnson & Johnson (JNJ) Will Announce Quarterly Sales of $20.21 Billion
Wall Street analysts expect that Johnson & Johnson (NYSE:JNJ) will report $20.21 billion in sales for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Johnson & Johnson’s earnings. The lowest sales estimate is $20.07 billion and the highest is $20.62 billion. Johnson & Johnson posted sales of $18.11 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.6%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, January 23rd.
According to Zacks, analysts expect that Johnson & Johnson will report full year sales of $20.21 billion for the current year, with estimates ranging from $76.21 billion to $80.09 billion. For the next fiscal year, analysts expect that the company will report sales of $81.56 billion per share, with estimates ranging from $80.72 billion to $82.66 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same period last year, the business posted $1.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.3% compared to the same quarter last year.
Shares of Johnson & Johnson (NYSE JNJ) opened at $142.46 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $144.35. The company has a market cap of $381,940.00, a PE ratio of 20.02, a price-to-earnings-growth ratio of 2.90 and a beta of 0.80.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s dividend payout ratio is 58.33%.
Several hedge funds and other institutional investors have recently made changes to their positions in JNJ. Parametric Portfolio Associates LLC increased its position in shares of Johnson & Johnson by 3.3% during the third quarter. Parametric Portfolio Associates LLC now owns 8,026,652 shares of the company’s stock valued at $1,043,545,000 after acquiring an additional 253,568 shares in the last quarter. Karpus Management Inc. bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $231,000. Wagner Bowman Management Corp increased its position in shares of Johnson & Johnson by 3.2% during the third quarter. Wagner Bowman Management Corp now owns 47,171 shares of the company’s stock valued at $6,132,000 after acquiring an additional 1,452 shares in the last quarter. Hikari Tsushin Inc. increased its position in shares of Johnson & Johnson by 8.3% during the third quarter. Hikari Tsushin Inc. now owns 53,810 shares of the company’s stock valued at $6,996,000 after acquiring an additional 4,130 shares in the last quarter. Finally, Burgundy Asset Management Ltd. increased its position in shares of Johnson & Johnson by 0.4% during the third quarter. Burgundy Asset Management Ltd. now owns 3,195,878 shares of the company’s stock valued at $415,496,000 after acquiring an additional 11,257 shares in the last quarter. 65.89% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.